**TOMM40** genetic variants associated with healthy aging and longevity: a systematic review

Sunny Chen1,2*, Sara M. Sarasua2, Nicole J. Davis2, Jane M. DeLuca2, Luigi Boccuto2, Stephen M. Thielke3 and Chang-En Yu1,4

**Abstract**

**Introduction:** Healthy aging relies on mitochondrial functioning because this organelle provides energy and diminishes oxidative stress. Single nucleotide polymorphisms (SNPs) in TOMM40, a critical gene that produces the outer membrane protein TOM40 of mitochondria, have been associated with mitochondrial dysfunction and neurodegenerative processes. Yet it is not clear whether or how the mitochondria may impact human longevity. We conducted this review to ascertain which SNPs have been associated with markers of healthy aging.

**Methods:** Using the PRISMA methodology, we conducted a systematic review on PubMed and Embase databases to identify associations between TOMM40 SNPs and measures of longevity and healthy aging.

**Results:** Twenty-four articles were selected. The TOMM40 SNPs rs2075650 and rs10524523 were the two most commonly identified and studied SNPs associated with longevity. The outcomes associated with the TOMM40 SNPs were changes in BMI, brain integrity, cognitive functions, altered inflammatory network, vulnerability to vascular risk factors, and longevity.

**Discussions:** Our systematic review identified multiple TOMM40 SNPs potentially associated with healthy aging. Additional research can help to understand mechanisms in aging, including resilience, prevention of disease, and adaptation to the environment.

**Keywords:** Aging, Healthy aging, Systematic review, TOMM40, Longevity

**Introduction**

In a recent report entitled “GHE: Life expectancy and healthy life expectancy,” the World Health Organization (WHO) confirmed that global life expectancy has increased by more than 6 years from 66.8 to 73.4 years in the past two decades [1]. However, the report also suggested that the Healthy Life Expectancy (HALE) did not increase proportionally with life expectancy; and on average, people lived with some form of disability for 9.7 years before death [1]. Bodily deterioration and increased susceptibility to diseases and medical conditions are inevitable parts of aging. The topic of longevity is no longer as simple as living long, but should also focus on the average length of a healthy life [2].

In the recent past, longevity studies have shifted to the study of phenotypic age. These studies proposed methods to identify reliable genetic biomarkers such as DNA methylation and leukocyte telomere length [3, 4] or exonic and non-coding single nucleotide polymorphism (SNP) variants [5] as surrogate measures to...
assess an individual’s healthy life expectancy. Many of these genetic factors were tested on mouse models; and the results suggested a close interconnection between genome maintenance and the underlying biological mechanisms of aging [6]. In 2014, a genome-wide association meta-analysis identified a novel locus containing the genes TOMM40/APOE/APOC1 that were linked to human longevity [7].

The TOMM40 gene maps on chromosome 19q13.32 and encodes the TOM40 protein, which is a subunit of the Translocase of Mitochondrial Outer Membrane (TOM) complex [8]. TOM is essential for mitochondrial functions including energy metabolism, cell apoptosis, lipid synthesis, and cellular homeostasis [9]. Several genetic association studies have revealed a strong link between genetic variants in multiple loci and exceptional human longevity [10, 11]; and TOMM40 was identified as one of the candidate genes. However, it is still unclear how TOMM40 variants directly influence the pathway of aging.

As the powerhouse of the cell, the function of mitochondria determines the efficacy of metabolic and signaling pathways. Recent studies demonstrated that elevated TOMM40 mRNA expression is associated with fold changes in mitochondria membrane potential (Δψm), mitochondrial DNA (mtDNA) copy number, respiratory rate, and ATP production [12, 13]. Mitochondrial functions are tightly regulated, and their dysfunctions can be associated with disease pathogenesis. For instance, elevated Δψm is observed in most tumors [14], while a decrease Δψm is linked to decreased ATP production rate, ATP depletion, and metabolic acidosis [15]. A decrease in mtDNA copy number is significantly associated with frailty (OR 0.91, 95% CI, 0.85–0.97), and is a strong predictor of all-cause mortality in age- and sex-adjusted multi-ethnic populations with a pooled hazard ratio of 1.47 (95% CI, 1.33–1.62) [16]. Impaired mitochondrial respiratory rate and decreased oxygen metabolism were associated with traumatic brain injury [17].

A recent review article suggested that mitochondrial dysfunction plays critical role as both primary and secondary events in Alzheimer’s disease (AD) pathogenesis through impaired energy metabolism, increased oxidative stress, and disturbed genomic homeostasis [18]. Research has investigated the association between TOMM40 SNPs and the development of AD. For instance, the poly-T length of SNP rs10524523 can increase the risk of AD [19–21] and the rs2075650 SNP was shown to be associated with higher AD risk in Asian and Caucasian populations [22]. Yet recent studies have revealed that mitochondria dysfunction can also lead to non-AD cognitive decline associated with aging in healthy individuals [12, 13, 23]. These findings suggested that there are non-pathogenic TOMM40 variants that may contribute to the pathways linked to longevity.

This review aims to investigate the possible connections between TOMM40 SNPs and longevity, independent of disease or medical conditions. In order to develop a deeper understanding of TOMM40 genetic variants in individuals without dementia, we conducted a systematic review of published research studies that examined the role of TOMM40 SNPs in the aging process. Since the TOM40 protein is a key component of mitochondria [24], it has been hypothesized that variants in the corresponding gene can be associated with improved or reduced mitochondrial functions. Such differences may lead to biological changes in aging. The goals of this systematic review were to: 1) identify the top candidate SNPs that are commonly identified in the studies, and 2) elucidate the associated age-related phenotype, and the specific allele that is associated with longevity and the aforementioned phenotypes. We sought to fill in the gap of knowledge by defining what is currently known about TOMM40 in healthy aging, and help shape directions for future research studies.

**Methods**

The peer-reviewed articles included in this systematic review were identified from the PubMed and Embase databases. We identified all studies that are associated with TOMM40, aging, and longevity. We conducted the review based on the guidelines of the PRISMA statement [25].

**Conceptualization of aging**

Aging entails a variety of phenotypic changes in cognitive function, frailty, metabolism, muscle-skeleton, height & weight, and vulnerability. Healthy aging involves the ability of the body to maintain proper mental and physical capability through these changes, and enables wellbeing in older age [26]. These capabilities are referred to the ability to meet their basic needs, to make decisions, to be mobile, to maintain relationships, and to contribute to the society [27]. Because there is no single physiologic parameter that covers all these domains, we used a broad approach in identifying research.

**Article selection**

The initial PubMed search terms used two combinations of (TOMM40[All Fields] AND AGING[All Fields]) and (TOMM40[All Fields] AND LONGEVITY[All Fields]). The search was conducted on all publications published before the 11th of March, 2022. We did not limit the search by the publication language. The same search terms were conducted in Embase for verification, and we combined the results from the two searches.
We manually reviewed the articles to identify the effect of TOMM40 genetic variants on healthy aging. Due to TOMM40 being commonly connected with AD; we excluded the studies that were solely focused on the prediction of dementia outcomes, and studies specifically included patients with AD diagnoses. Current RNA quantification methodologies have limited capability to distinguish between TOMM40 mRNA and its pseudogenes [13]. Due to this reason, studies that focused purely on TOMM40 RNA may generate contradicting results. Thus, studies on TOMM40 RNA and TOM40 protein levels that did not include SNP data were excluded from the review. We excluded articles that used non-human models for investigation.

Data extraction
We summarized the articles by extracting the information including author, year of publication, SNP accession numbers (rs ID) investigated in the study, and proposed phenotypes associated with the SNPs. We also listed all the SNPs of the neighboring genes (including PVRL2, APOE, and APOC1) that are co-investigated from each study. We have noted the specific variants that were tied to the associated phenotype unless it is not specified in the study. For the interest of investigation into the SNP effect on aging, we carefully extracted only age-associated phenotypes (including nonpathogenic changes associated with BMI, cognitive function, and vulnerability) from each study. Additionally, we compiled a list of the most commonly identified TOMM40 SNPs and ranked them based on the number of appearances in different studies.

Results
The initial search identified 123 articles. By screening through the titles and abstracts of the articles and evaluating the results, we identified 24 studies that met the inclusion and exclusion criteria to be included in the review. Figure 1 presents the flowchart that describes the literature selection process.

All of the research studies were published between the years 2011 and 2022. The number of TOMM40 SNPs investigated in each study varied widely, ranging from one to ten. Half of the studies were exploratory studies such as Genome-Wide Association Studies (GWAS) and SNP panels [7, 10–, 28–35]. The remaining studies [36–, 37–49] specifically selected a TOMM40 SNP or SNPs of interest. Sixteen unique SNPs were investigated in the studies. In addition to the TOMM40 SNPs, eight studies investigated polymorphisms of neighboring genes of...
**Brain integrity and cognitive ability**

Nine studies investigated the effect of TOMM40 SNPs on cognitive ability among individuals without AD [31, 32, 35, 37, 42, 44, 46, 48, 49]. The evaluations differed across research studies but were mainly focused on episodic memory performances and verbal/vocabulary abilities. Although there are inconsistent findings, five studies reported that the SNP rs10524523 is associated with cognitive decline [37, 42, 44, 46, 48]. Deters et al. suggested that the effect could be attenuated or exacerbated due to concomitant APOE variants in non-Hispanic Black populations [37]. Thus, the impact of TOMM40 may be affected by the presence of other risk factors and may contribute to inconsistent reports. One study done by Ferencz et al. reported no association between TOMM40 SNP and cognition [32].

Two studies examined the effect of TOMM40 SNPs on brain integrity (in the form of thinning of different brain regions) using brain imaging. These studies hypothesized that there would be phenotypic changes in the brain of non-AD individuals. Of the two studies, Burggren et al. found an association between SNP rs10524523 and entorhinal cortex thinning [39], while the other study reported no association between TOMM40 SNPs and cortical thinning/hippocampal volume [43].

**Longevity**

All nine studies that investigated associations between TOMM40 SNPs and longevity found at least one SNP associated with human longevity [7, 10, 29, 30, 34, 40, 41, 45, 47]. Three studies presented their findings as TOMM40 haplotype data instead of a single SNP analysis. Among the SNPs inspected, the association of the rs2075650-A variant with increased longevity is consistent across multiple studies. This finding was consistent for the American, European, and Chinese cohorts.

**Body mass index**

Two studies found an association between one single TOMM40 SNP (rs2075650) with Body Mass Index (BMI) status. Guo et al. reported that being homozygous at rs2075650-g allele is associated with lower BMI [33]. While Kulminski et al. suggested that only heterozygous in A/g is associated with lower BMI [38].

**Other factors**

Two studies reported that the rs2075650-g allele can alter human inflammatory response and susceptibility to diseases. Lamparello et al. found a significant association between higher severity in traumatic injury due to predisposition to anti-inflammatory response with rs2075650-g allele [28]. The author suggested a differential inflammation profile in patients who carried the g allele. Such inflammatory predisposition can lead to greater disease severity and a higher mortality rate in the elderly. Similarly, Gui et al. suggested that the genetic effect of rs2075650-g allele aggregates with vascular risk factors (VRF), and increases the vulnerability to global cognitive decline [36].

Table 2 summarizes the most commonly investigated TOMM40 SNPs and the associated health factors across all the studies. The most commonly reported and investigated polymorphism is rs2075650 – included in 11 different studies. SNP rs10524523 is ranked number 2, and has appeared in eight studies. The SNPs rs157582, rs71352238, and rs8106922 were specific to longevity, and were usually investigated together: rs157582 has been examined in 4 studies, 3 times for rs71352238, and 2 for rs8106922.

**Discussion**

This systematic review identified the most commonly studied TOMM40 SNPs and the age-associated health factors that were investigated for these genetic variants. The studies we identified indicate that three main age-related health factors may be associated with TOMM40 SNPs: brain integrity, body mass index, and cognitive function. Brain integrity is associated with SNP rs10524523. BMI is associated with SNP rs2075650. Both SNPs are also related to cognitive function in non-AD individuals. Additionally, all of the TOMM40 SNPs listed in Table 2 are associated with human longevity. We will discuss the potential mechanisms for each of these.

It is uncertain why the non-AD aging-associated phenotypes of the gene TOMM40 have only been investigated since 2011, the date of the earliest publication. However, Roses et al’s 2016 study have pointed out that early GWAS studies have deliberately excluded the analyses of the APOE-TOMM40 linkage disequilibrium (LD) region, which resulted limited understanding in the TOMM40 gene [50]. Additionally, due to strong LD between the APOE and TOMM40 SNPs, many strong GWAS signals for TOMM40 SNPs were interpreted as APOE hits in early research studies [32]. Early interpretations of the gene TOMM40 may discourage research
| Authors       | Year | Cohort Ancestry                          | Study Type          | SNPs rs Number and Allele Associated with the Phenotype | TOMM40-Associated Phenotype Summary |
|---------------|------|------------------------------------------|---------------------|--------------------------------------------------------|-------------------------------------|
| Li [49]       | 2022 | European                                 | Selected Single SNP | rs2075650-g                                           | Led to less language comprehension network strength in females |
| Gui [36]      | 2021 | Chinese                                  | Selected Single SNP | rs2075650-g                                          | Increased vulnerability to global cognitive decline due to smoking, drinking, physical inactivity, obesity, total cholesterol (include LDL), triglycerides, diabetes, and hypertension |
| Liu [10]      | 2021 | Chinese                                  | SNP Array           | rs2075650-A                                           | Increased longevity                |
| Deters [37]   | 2021 | Non-Hispanic Black & Non-Hispanic White  | Selected Single SNP | rs10524523-S                                          | Altered age-related global cognition, episodic memory, and visuospatial ability segregated by APOE variant: TOMM40 SNP in APOE ε3/ε3: Faster decline TOMM40 SNP in APOE ε4+: Slower decline |
| Lamparello [28]| 2020 | Conducted in the United Statesb         | SNP Array           | rs2075650-g                                          | Altered inflammation response (increased severity) in age-associated blunt injuries |
| Kulmins [38]  | 2019 | Caucasian                                | Selected Multiple SNPs | rs2075650-A/g                                       | Lower BMI                           |
| Yashin [29]   | 2018 | Mixed Population (World-Wide)            | GWAS                | rs73052307-T rs2075650-A rs71352238-T rs34095326-G rs157582-G | Increased longevity               |
| Yashin [30]   | 2018 | Mixed Population (World-Wide)            | GWAS                | rs2075650-A rs8106922-A rs157582-C rs71352238-T rs769449-G | Increased longevity               |
| Arpawong [31] | 2017 | Conducted in the United Statesb         | GWAS                | rs71352238-G rs2075650-g rs157582-A rs769449-a | Delayed verbal recall in non-AD |
| Burggren [39] | 2017 | Conducted in the United Statesb         | Selected Single SNP | rs10524523-L                                          | Thinner entorhinal cortex in non-AD |
| Shadyab [40]  | 2017 | Conducted in the United Statesb         | Selected Multiple SNPs | rs2075650                                          | Increased longevity in women       |
| Lin [41]      | 2016 | Chinese                                  | Haplotype           | rs7254892-A rs57580-A rs2075649-A rs2075650-A rs157582 T rs8106922-A rs1160985-T | Increased longevity               |
**Table 1** (continued)

| Authors       | Year | Cohort Ancestry       | Study Type          | SNPs rs Number and Allele Associated with the Phenotype | TOMM40-Associated Phenotype Summary |
|---------------|------|-----------------------|---------------------|--------------------------------------------------------|-------------------------------------|
| Payne [42]    | 2016 | European              | Selected Single SNP | N/A rs10524523-S                                      | Slower vocabulary ability decline in non-AD |
| Wennberg [43] | 2016 | Conducted in the United States | Selected Single SNP | N/A rs10524523                                      | No association with cortical thinning in non-AD |
| Deelen [7]    | 2014 | European              | GWAS                | N/A rs2075650 rs4420638-A                              | Increased longevity                   |
| Greenbaum [44] | 2014 | Israeli Jewish       | Selected Single SNP | N/A rs10524523-S                                      | Better cognition in non-AD            |
| Lu [45]       | 2014 | Chinese               | Selected Multiple SNPs | rs12972156-A rs199825-A rs395908-C rs2075650-A/g rs405509-A | Increased longevity                   |
| Ferencz [32]  | 2013 | European from Island of Kungsholmen | SNP Array | N/A rs11556505 rs2075650                               | No association with hippocampal volume and episodic memory performance in non-AD |
| Zhang [35]    | 2013 | Conducted in the United States | GWAS                | N/A rs115881343 rs769449                              | Cognitive decline in non-AD          |
| Caselli [46]  | 2012 | Conducted in the United States | Selected Single SNP | N/A rs10524523                                      | Age-related memory performance in non-AD |
| Guo [33]      | 2012 | Mixed Population (World-Wide) | GWAS                | N/A rs2075650-g                                      | Low BMI                              |
| Sebastiani [34] | 2012 | Conducted in the United States | GWAS                | N/A rs2075650-A                                      | Increased longevity                   |
| Maruszak [47] | 2012 | European              | Selected Single SNP | N/A rs10524523-L                                     | Decreased longevity                   |
| Johnson [48]  | 2011 | Conducted in the United States | Selected Single SNP | N/A rs10524523-VL                                    | Cognitive decline in non-AD          |

**rs#: Accession number for specific SNPs**

**BMI**: Body Mass Index

**non-AD**: Non-Alzheimer’s disease patients

**N/A**: Not available

a Located at APOE-to-APOC1 intragenic region

b Studies conducted in the United States with mixed population

---

**Table 2** Top 5 Commonly Investigated TOMM40 SNPs From Studies and Their Association with Age-Related Health Factors and Longevity

| Common TOMM40 SNPs | Times Identified | Associated Age-related Health Factor and/or Longevity |
|--------------------|------------------|-------------------------------------------------------|
| rs2075650          | 12               | BMI [33, 38]; Cognitive Function [31, 49]; Longevity [7, 10, 29, 30, 34, 40, 41, 45]; Cognitive Function [32]; Altered Inflammatory Network [28]; Vulnerability to Vascular Risk Factors [36] |
| rs10524523         | 7                | Brain Integrity [39]; Cognitive Function [37, 42, 44, 46, 48]; Longevity [47] |
| rs157582           | 4                | Longevity [29–31, 41] |
| rs71352238         | 3                | Longevity [29–31] |
| rs8106922          | 2                | Longevity [30, 41] |

**BMI**: Body Mass Index

* Investigated, but no direct association found between the SNPs and the health factor
groups from investigating into it; and may explain why topics in TOMM40 and non-AD aging have only been investigated after 2011. Aside from longevity, the most commonly investigated aging-associated phenotype is brain function. It is to be expected that brain integrity and cognition receive so much attention, as the mitochondrial cascade and mitochondrial dysfunction have become some of the most predominant hypotheses in AD studies [51, 52].

SNP rs2075650

The rs2075650 SNP (depicted in Fig. 2) is located within the non-coding region of TOMM40: c.275-31A > G [53]. The minor allele frequency (MAF) for g is approximately 0.124; the frequency is more common in the European (Mean MAF: 0.131) and African populations (Mean MAF: 0.141), and less common in East Asian populations (Mean MAF: 0.092) [54, 55]. This SNP is strongly associated to exceptional longevity [7, 10, 29, 34, 40, 41, 45]. Multiple studies have reported that the major allele rs2075650-A has highly significant \((p < 0.001)\) predictability of survival to \(\geq 90\) years old in Chinese [41, 45], European [7], and admixed (White, Black, and Hispanic) populations [29, 34, 40]. Its minor allele rs2075650-g is associated with various biological changes including weakened cognitive function [31, 49], decreased BMI [33, 38], altered inflammatory networks [28], and increased vulnerability to vascular risk factors [36].

Two reviewed articles pointed out that the rs2075650-g allele is linked to weakened verbal ability in non-AD individuals. Arpawong et al. reported an association with delayed verbal recall ability [31]; and Li et al. reported an overall decrease in language comprehension network strength in the female population, correlated with increasing age [49]. It has also been suggested that rs2075650 has a strong association with AD, with an odds ratio of 4.178 \((p\text{-value} = < 0.001)\) in Asian and Caucasian populations [22]. Another meta-analysis found similar associations with AD in European and Korean populations but was unable to replicate the result in the Chinese population [57]. There was one study that demonstrated that the rs2075650-g allele is linked to executive dysfunction and lifetime depression [58]. The underlying biological mechanism behind this SNP variant is still unclear, however, it is known that it has a negative effect on both AD and non-AD populations. A recent study that proposed an accurate surrogate quantification of TOMM40 transcripts did not find any evidence that the minor allele can affect mRNA levels in both AD and non-AD brain tissues [13]. This suggested that the function of the SNP is not as straightforward as it might seem to be, and may belong to a more complicated genetic regulatory network.

Homozygosity of the g allele is also associated with a lower BMI score [33]. A 1994 review article that proposed an association between AD and weight loss [59], thus we hypothesized that the relationship between low BMI and impaired cognition may be linked to the SNP. Meta-analyses have shown that unintentional weight loss occurs commonly in the elderly [60], and have pointed out that it has a significant association with all-cause mortality in the elderly [61, 62]. These findings suggest that BMI maintenance is an important factor in healthy aging, and may be indirectly mediated by this TOMM40 SNP.

Two studies have pointed out that the minor allele rs2075650-g altered biochemical pathways can lead to increased susceptibility to bodily decline and disease severity in the elderly [28, 36]. In 2021, Gui et al. reported that vascular risk factors (such as current smoking, current drinking, physical inactivity, obesity, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high lipoprotein cholesterol, diabetes, and hypertension) and rs2075650-g variant could interact synergistically [36]. The g allele increased an individual’s susceptibility to bodily damages due to the aforementioned vascular risk factors, and lead to decline in cognitive performance. Mitochondrial functional variation due to the rs2075650-g
allele may provide an explanation for the connections in weight loss, cognitive decline, and vulnerability to higher disease severity. Multiple studies demonstrated that individuals who are homozygous in the A allele, and heterozygous in A/g alleles have longer lifespans [29, 30, 34, 45]. This makes sense as being free of diseases often equates to a prolonged lifespan. However, we are unable to directly ascertain the causal relationship between the TOMM40 genetic variants and increased lifespan through the studies. It is still unclear if these individuals lived longer because the alleles made them more resilient to weakening due to the aging process; or because the alleles are associated with lesser disease risks.

**SNP rs10524523**

Different from other TOMM40 SNPs, rs10524523 (depicted in Fig. 2) is a poly-T extension that consists of Short (S), Long (L), and Very Long (VL) variants located within the intron 6: c.644-938_644-904T(12_46) [21]. The findings from the reviewed article suggested that in AD patients, the L variant is associated with higher AD risk and increased cognitive decline in APOE e4 carriers [21, 47]. While the VL variant is associated with earlier disease onset in APOE e3/e3 carriers [63]. The non-AD studies reviewed in this article suggested a consistent finding of L and VL variants associated with a higher rate of cognitive decline independent of APOE isoform. These findings hold true in non-Hispanic Black APOE e4 carriers as well [37].

As an intronic gene variation, it is highly unlikely that the rs10524523 SNP may disrupt protein folding that can significantly affect the stability of the TOM complex. However, the reviewed articles pointed out a close association of the poly-T SNP with different forms of brain and cognitive decline [37, 42, 44, 46, 48]. This suggested that longer variants of rs10524523 are linked to certain biochemical cascades that could increase the brain’s vulnerability to environmental insults.

In a recent study, Lee et al. correlated TOMM40 RNA level with the mitochondrial functions (including mtDNA copy number and membrane potential) of human cell lines in response to oxidative stress [13]. The study reported that after H2O2 treatment, TOMM40 RNA levels were increased by 1.2 to 1.5-fold, mitochondrial DNA copy number was decreased by 40–80%, and membrane potential was decreased by 25–80% compared to untreated cell cultures [13]. Their findings suggested that upregulation of TOMM40 RNA level is associated with mitochondrial dysfunction or its response due to stress; and that it may be a biochemical mechanism for cells to cope with damages to the cells. Therefore, different SNP variations in TOMM40 may contribute to the overall efficacy gene expressions and transcriptional regulations in response to damages. The biological effect of the length in rs10524523 is currently unknown; however, studies have suggested that the VL variant is associated with a significantly higher TOMM40 mRNA expression level, as compared to the S variant in both control and AD groups [13, 64]. As noted above, the rs10524523–VL variant is associated with cognitive decline. A possible explanation of such observation is that cognitive decline due to aging is associated with mitochondrial dysfunction. Alzheimer’s disease may be an extreme form of the aging process that resulted from a weaker mitochondria complex coupled with other genetic factors.

**Additional TOMM40 SNPs**

Multiple studies have pointed out additional SNPs including rs71352238 (c.-245 T > C), rs157582 (c.435 +33C > T), and rs8106922 (c.644-2321A > G) that are linked to increased lifespan. A single GWAS study also showed SNPs rs71352238 and rs157582 are also associated with delayed verbal recall [31]. However, due to limitations in research methods and limited evidence of their association with other medical conditions, their causal relationship with longevity and healthy aging can only be speculated. These polymorphisms, in sequential order, are located at the 5’ upstream region, intron 4, and intron 6 of TOMM40 (depicted in Fig. 2). Including rs2075650 and rs10524523, the top five SNP candidates associated with aging and longevity are all located in non-coding regions. Two possible reasons may explain the potential biological importance of variances in intronic SNPs.

First, the TOM complex is essential for the recognition and importation of proteins into the mitochondria [8, 24]. Therefore, the mitochondrial complex does not tolerate other TOM40 protein isoforms or misfolding resulting from amino acid changes. There are currently no studies that have reported any SNPs within the exon regions of TOMM40 that would translate into different functional protein variants in humans. In 2007, Kinoshita et al. reported a protein variant TOM40B with 28 amino acid deletion at C-terminus, that would form a larger protein complex in a rat model [65]. This opens up the possibility of seeing functionally truncated TOM40 isoforms in humans. A UniProt search of the gene revealed that there are two human isoforms; one canonical, and another isoform due to alternative splicing [66]. In 2011, Mager et al. successfully characterized two human TOMM40 protein isoforms that have deletions in their N-terminus [67]. However, the authors did not observe any functional differences that could imply any biological significance [67]. It is also unknown if there are SNPs that contribute to the expression of the truncated isoforms.

Second, multiple regulatory elements can interact with the non-coding regions of the TOMM40 gene, and the
SNPs can alter mRNA expression by affecting the binding affinities. Two earlier studies have suggested that the rs10524523-VL variant is associated with a higher expression level of TOMM40 mRNA and TOM40 protein, and the increased expression is protective against the toxic effects of exogenous beta-amyloid (Aβ) [12, 64]. However, a meta-analysis conducted in 2015 concluded that rs2075650 can also affect TOMM40 expression level, and over-expression can lead to the accumulation of amyloid precursor protein [57]. It is not known why both SNPs can lead to over-expression of RNA and protein level can have a very different biological effect. This suggested that these SNPs may also play different roles in other regulatory pathways that have yet to be properly examined. For instance, one study has shown that TOMM40 can be regulated by long non-coding RNA (lncRNA) [68]. It is unknown if the gene itself produces any non-coding RNAs, but it is possible that intronic SNPs may alter the transcription of both functional and non-function RNA products. Another example is pseudogene regulation. A study reported that TOMM40 pseudogene transcripts are expressed across different tissue types in both cancer and non-cancer cells [69]. Pseudogene-derived transcripts compete for gene regulatory and post-transcriptional regulatory elements [69]. Therefore, polymorphisms that contribute to differences between TOMM40 and its pseudogene may result in changes in enhancer activities and promoter interactions of the gene networks.

Limitations
Our literature review attempted to include research topics associated with TOMM40, healthy aging, and longevity by searching the key words across all fields; but not solely on article titles and abstracts. We used broad terminologies such as “Aging” and “Longevity” in hoping to encompass most existing studies associated with aging-related phenotypes and human longevity. However, such broad terms may result in failure to capture research studies that used very specific keywords that are related to mental or physical disabilities related to the elderly. Approximately two-third of the studies identified in the systematic review investigated into very specific TOMM40, or identify SNP of interest using commercially available SNP arrays. This may contribute to an overemphasis of specific TOMM40 SNP. Additionally, because the remaining one-third of the studies were GWAS studies, many did not propose clear biological mechanisms that could explain how the SNPs could be tied to longevity or healthy aging.

It has caught our attention that most longevity studies simply compared the chronological ages between participants of different genetic haplotypes, or simply set the cutoff point (i.e., 90 years old) for longevity. Current studies investigating the association between TOMM40 and longevity have not accounted for healthy aging (i.e., changes in mental and/or physical capabilities due to aging progress). Although people from a specific TOMM40 genetic subgroup may have a longer lifespan, it is not known whether these people also have a longer HALE (i.e., having lesser or delayed onset of disabilities), or they simply have a longer life expectancy. We recommend that future studies should also take years of a healthy life into account to determine if the study participants truly lived a long and healthy life.

Conclusions
Additional studies are recommended to ascertain the relationship of TOMM40 genetic variations with other chronic conditions, number of comorbidities, and frailty. Although our review did not consider Alzheimer’s dementia or other diseases, it is possible that the same variations have effects on both disease and healthy aging. Considering disease states could elucidate not just the underlying mechanisms behind longevity, but also provide insights on increasing healthy life expectancy.

The five candidate SNPs discussed in this paper can become potential candidates to be examined together for future studies on aging-associated comorbidities. Aside from the commonly investigated SNPs rs10524523 and rs2075650, there are currently no reports on how the other three candidates (rs71352238, rs157582, and rs8106922) can influence TOMM40 RNA or protein level. Furthermore, researchers have yet to find the biological implication of rs8106922 and have not postulated any specific mechanisms that can tie to increased longevity. Thus, functional studies of the 5 intronic SNPs (rs10524523, rs2075650, rs71352238, rs157582, and rs8106922) as well as gene sequencing of TOMM40 are warranted.

Additional work is required to ascertain how these SNP candidates can affect inter-gene and intra-gene regulations, RNA expression, and protein expression. Future research direction should also focus on examining the intronic SNPs and their associations with alternative splicing of truncated TOM40 proteins. These investigations can identify the potential biological significance of the polymorphisms and protein variances, and help devise potential therapies that can improve the health of individuals who did not inherit longevity alleles to become more resilient against age-related disabilities. These researches will improve the overall quality of life, and decrease the gap between healthy life expectancy and life expectancy.
Abbreviations
AD: Alzheimer’s Disease; BMI: Body Mass Index; HALE: Healthy Life Expectancy; mtDNA: Mitochondrial DNA; SNPs: Single Nucleotide Polymorphisms; TOM: Translocase of Mitochondrial Outer Membrane; VRF: Vascular Risk Factor.

Acknowledgements
Not applicable.

Authors’ contributions
S.C. drafted and wrote the manuscript with support from L.B. and S.M.S.. S.C. conducted literature search, review, and extraction of data. C.E.Y. contributed background knowledge in gene of interest. S.M.S., N.J.D., J.M.D., L.B., S.M.T., and C.E.Y. contributed in critical revision and commentary. All authors have reviewed the results and approved the final version of the manuscript.

Funding
Article processing charge funded by Clemson University Open Access Publishing Fund, and Clemson University Center for Research on Health Disparities.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Geriatric Research, Education, and Clinical Center, Puget Sound VA Medical Center, VA Puget Sound Healthcare System, 1660 S Columbia Way, Seattle, WA 98108, USA. 2Healthcare Genetics Program, School of Nursing, Clemson University, Clemson, SC, USA. 3Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. 4Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA.

Received: 31 March 2022   Accepted: 23 July 2022
Published online: 13 August 2022

References
1. GHE. Life expectancy and healthy life expectancy. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy. Accessed 11 Mar 2022.
2. Crimmins EM. Lifespan and Healthspan: past, present, and promise. Gerontologist. 2013;53(6):901–11.
3. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573–91.
4. Liu J, Kuo PL, Horvath S, Crimmins E, Ferrucci L, Levine M. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study. PLoS Med. 2018;15(12):e1002718.
5. Breitbach ME, Greenspan S, Resnick NM, Perera S, Gurkar AU, Absher D, et al. Exonic variants in aging-related genes are predictive of phenotypic aging status. Front Genet. 2019;10:1277.
6. Vermeij WP, Hoeijmakers JH, Pothof J. Genome integrity in aging: human syndromes, mouse models, and therapeutic options. Annu Rev Pharmacol Toxicol. 2016;56:427–45.
7. Deelen J, Beekman M, Uh HW, Broer L, Ayers KL, Tan Q, et al. Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. Hum Mol Genet. 2014;23(16):4420–32.
8. Humphries AD, Streimann IC, Stojanovski D, Johnston AJ, Yano M, Hoogenaar NJ, et al. Dissection of the mitochondrial import and assembly pathway for human Tom40. J Biol Chem. 2005;280(12):11535–43.
9. Chacinska A, Koehler CM, Milenkovic D, Ligthov T, Pflanner N. Importing mitochondrial proteins: machineries and mechanisms. Cell. 2009;138(4):628–44.
10. Liu X, Song Z, Li Y, Yao F, Fang M, Bai C, et al. Integrated genetic analyses revealed novel human longevity loci and reduced risks of multiple diseases in a cohort study of 15,651 Chinese individuals. Aging Cell. 2021;20(3):e13323.
11. Fortney K, Dobriban E, Garagani P, Pirazzini C, Monti D, Mari D, et al. Genome-wide scan informed by age-related disease identifies loci for exceptional human longevity. PLoS Genet. 2015;11(12):e1005728.
12. Zeitlow K, Charlambous L, Ng I, Gagnani S, Mihovilovic M, Luo S, et al. The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2017;1863(11):2973–86.
13. Lee E-G, Chen S, Leong L, Tulloch J, Yu C-E. TOMM40 RNA expression in Alzheimer’s disease brain and its implication in mitochondrial dysfunction. Genes. 2021;12(6):871.
14. Porporato PE, Filigheddu N, Pedro JS, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265–80.
15. Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003;10(6):709–17.
16. Ashar FN, Moes A, Moore AZ, Grove ML, Chaves PHM, Coresh J, et al. Association of mitochondrial DNA levels with frailty and all-cause mortality. J Mol Med (Berl). 2015;93(2):177–86.
17. Verweij BH, Muzelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP. Impaired cerebral mitochondrial function after traumatic brain injury in humans. J Neurosurg. 2000;93(5):815–20.
18. Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener. 2020;15(1):30.
19. Lyall DM, Harris SE, Bastin ME, Munoz Maniega S, Murray C, Lutz MW, et al. Alzheimer’s disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiol Aging. 2014;35(6):1513 e1525–33.
20. Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, et al. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol. 2011;68(8):1013–9.
21. Rosem AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s disease. Pharmacogenomics J. 2010;10(5):375–84.
22. Huang H, Zhao J, Xu B, Ma X, Dai Q, Li T, et al. The TOMM40 gene rs2075650 polymorphism contributes to Alzheimer’s disease in Caucasian and Asian populations. Neurosci Lett. 2015;628:142–6.
23. Gottschalk WK, Lutz MW, He YT, Saunders AM, Burns DK, Roses AD, et al. The broad impact of TOMM40 on neurodegenerative diseases in aging. J Parkinsons Dis Alzheimers Dis. 2014;1(1):12.
24. Hoogenaar NJ, Ward LA, Ryan MT. Import and assembly of proteins into mitochondria of mammalian cells. Biochim Biophys Acta. 2002;1592(1):97–105.
25. Liberatori A, Altman DG, Tetzlaft J, Mulrow C, Gotzsche PC, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.
26. Rudnicka E, Napierala P, Podgurina A, Meczekalski B, Smolarczyk R, Grymowicz M. The World Health Organization (WHO) approach to healthy ageing. Maturitas. 2020;139:6–11.
27. Bead J, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel JP, et al. The world report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145–54.
28. Lampaello AJ, Namas RA, Schimunek L, Cohen M, El-Dehaiby F, Yin J, et al. An aging-related single-nucleotide polymorphism is associated with altered clinical outcomes and distinct inflammatory profiles in aged blunt trauma patients. Shock. 2020;53(2):146–55.
29. Yashin AI, Arbeev KG, Wu D, Arbeeva LS, Bagley O, Stallard E, et al. Genetics of human longevity from incomplete data: new findings from the long life family study. J Gerontol. 2018;73(11):1472–81.
30. Yashin AI, Fang F, Kovalt M, Wu D, Duan M, Arbeev K, et al. Hidden heterogeneity in Alzheimer's disease: insights from genetic association studies and other analyses. Exp Gerontol. 2018;107:148–60.

31. Aspawong TE, Pendleton N, Mekki K, McAdooe JJ, Gatz M, Armosskus C, et al. Genetic variants specific to aging-related verbal memory: insights from GWAS in a population-based cohort. PLoS One. 2017;12(8):e0182448.

32. Ferencz B, Lautka EJ, Lovdén M, Kalpouzos G, Keller L, Graff C, et al. The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age. Front Hum Neurosci. 2013;7:198.

33. Guo Y, Lanktree MB, Taylor KC, Hakonarson H, Lange LA, Keating BJ. The IBC 50K SNP array BMI consortium: gene-centric meta-analyses of 108,912 individuals confirm known body mass index loci and reveal three novel signals. Hum Mol Genet. 2013;22(1):184–201.

34. Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW, et al. Genetic signatures of exceptional longevity in humans. PLoS One. 2012;7(1):e29848.

35. Zhang C, Pierce BL. Genetic susceptibility to accelerated cognitive decline in the US health and retirement study. Neurobiol Aging. 2014;35(6):1512.e115–18.

36. Gui W, Qu C, Shao Q, Li J. Associations of vascular risk factors, APOE and TOMM40 polymorphisms with cognitive function in dementia-free Chinese older adults: a community-based study. Front Psychiatry. 2021;12:6773.

37. Deters KD, Mormino EC, Yu L, Lutz MW, Bennett DA, Barnes LL. TOMM40-APOE haplotypes are associated with cognitive decline in non-demented blacks. Alzheimers Dement. 2021;17(8):997–1005.

38. Kalpouzos G, Hummer JF, Liu C, Wang J, Torkamani A, et al. Replication of genome-wide association studies for age of onset of Alzheimer’s disease. Int J Geriatr Psychiatry. 2020;35(8):848–56.

39. Burggren AC, Mahmood Z, Harrison TM, Siddarth P, Miller KJ, Small GW, et al. The TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpharmacologic aging. Neurobiol Aging. 2016;39:217–26.

40. He Y, Li C, Yang Y, Li Y, Wang Y, Yang Y, et al. Meta-analysis of the rs2075650 polymorphism and risk of Alzheimer disease. Aging Cell. 2019;18(1):e12869.

41. Lin R, Zhan Y, Duan M, Liao X, Gong G, Hu J, et al. Association of common variants in TOMM40/APOE/APOC1 region with human longevity in a Chinese population. J Hum Genet. 2016;61(4):323–8.

42. Payton A, Sindravecz P, Pessoa V, Platt H, Moran M, Ollier W, et al. TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpharmacologic aging. Neurobiol Aging. 2016;39:217–26.

43. Wennberg AMV, Spira AP, Pettigrew C, Soldan A, Zipunnikov V, Rebok GW, et al. Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. J Neurol Sci. 2016;365:89–95.

44. Greenbaum L, Springer RR, Lutz MW, Saunders AM, Reiman EM, et al. Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimer's Dement. 2012;8(6):490–5.

45. Maruszak A, Peplovska B, Safarov K, Chodakowska-Zebrowska M, Barcowska M, Zekanowski C. TOMM40-rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity. J Alzheimers Dis. 2012;28(2):309–22.

46. Johnson SC, Lar Rue A, Herrmann BP, Xu G, Kosic KL, Jonaitis EM, et al. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimer's Dement. 2011;7(4):456–65.

47. Li T, Pappas C, Le ST, Wang Q, Klinedinst BS, Larsen BA, et al. APOE, TOMM40, and sex interactions on neural network connectivity. Neurobiol Aging. 2022;109:158–65.

48. Roses A, Sundseth S, Saunders A, Gottschalk W, Burns D, Lutz M. Understanding the genetics of APOE and TOMM40 role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. Alzheimers Dement. 2016;12(6):687–94.

51. Swedlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta. 2014;1842(8):1219–31.